Stockscreener 앱 받기
62.03
11.99%
6.64
시장 영업 전:
61.70
-0.33
-0.53%
Dianthus Therapeutics Inc 주식(DNTH)의 최신 뉴스
Dianthus Therapeutics stock hits 52-week high at 58.45 USD - Investing.com
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week HighShould You Buy? - MarketBeat
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views - Benzinga
Guggenheim raises Dianthus Therapeutics stock price target to $200 on autoimmune potential - Investing.com Canada
Dianthus Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
DNTH: Accelerated CIDP and MMN trials target 2024 milestones with patient-friendly, differentiated protocols - TradingView
DNTH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Tuesday - Defense World
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A 37% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next - TechStock²
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference - Bitget
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 6.1%Time to Buy? - MarketBeat
Patient Square Capital LP Makes New Investment in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (DNTH): Analyst Consensus Points to a Promising 46.82% Upside Potential - DirectorsTalk Interviews
Ideas Watch: Whats the RSI of Dianthus Therapeutics Inc stockOil Prices & High Return Trade Guides - baoquankhu1.vn
RA Capital discloses 6.0% Dianthus Therapeutics (DNTH) ownership stake - Stock Titan
Point72 boosts Dianthus Therapeutics (DNTH) stake to 6.9% passive ownership - Stock Titan
Transcript : Dianthus Therapeutics, Inc. Presents at Guggenheim Securities Emerging Outlook - marketscreener.com
Assessing Dianthus Therapeutics (DNTH) Valuation After A Strong Year And Recent Share Price Pullback - Sahm
Will Dianthus Therapeutics Inc. (87E) stock beat international competitionPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans - MarketBeat
Will Dianthus Therapeutics Inc. stock go up in YEARPortfolio Value Summary & Verified Short-Term Plans - mfd.ru
DNTH: Key 2026 clinical milestones and strong commercial outlook drive optimism for pipeline success - TradingView
DNTH: Pivotal trial readouts and strong financials position the pipeline for major commercial impact - TradingView
What 4 Analyst Ratings Have To Say About Dianthus Therapeutics - Benzinga
Can Dianthus Therapeutics Inc. deliver alpha2025 Winners & Losers & Verified Momentum Stock Alerts - mfd.ru
Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00 - MarketBeat
Is Dianthus Therapeutics Inc. a turnaround storyBear Alert & Verified Momentum Stock Alerts - mfd.ru
Candriam S.C.A. Purchases 60,852 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
How Investors Are Reacting To Dianthus Therapeutics (DNTH) US$600 Million Universal Shelf Registration - simplywall.st
Assessing Dianthus Therapeutics (DNTH) Valuation After New US$600m Shelf Registration Filing - Sahm
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - 富途牛牛
Dianthus CEO joins analyst-led fireside chat at Guggenheim summit - Stock Titan
Dianthus Therapeutics (DNTH) Price Target Increased by 10.51% to 75.99 - Nasdaq
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update - MarketBeat
Jefferies Financial Group Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Given New $81.00 Price Target at Jefferies Financial Group - MarketBeat
Will Dianthus Therapeutics Inc. stock keep outperforming rivalsJuly 2025 EndofMonth & Weekly Top Stock Performers List - mfd.ru
Biotech Stocks To Follow Today – January 30th - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biotech Stocks To Follow TodayJanuary 30th - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD By Investing.com - Investing.com India
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: A Biotech Gem with 21.98% Upside Potential - DirectorsTalk Interviews
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week HighShould You Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 54.05 USD - Investing.com
Oppenheimer Boosts Price Target on Dianthus Therapeutics to $125 From $62, Keeps Outperform Rating - marketscreener.com
Oppenheimer raises Dianthus Therapeutics stock price target to $125 from $62 - Investing.com Canada
Dianthus Therapeutics may issue up to $600 million in securities - marketscreener.com
Dianthus Therapeutics May Issue Up To $600 Million In Securities - TradingView
Dianthus Therapeutics (DNTH) Is Up 18.7% After Claseprubart Trial Progress Reshapes Its Autoimmune Focus - Sahm
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a Potential 23% Upside in the Biotech Sector - DirectorsTalk Interviews
0.11%
6.00%
자본화:
|
볼륨(24시간):